Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
-7.57M
-
Total reported value, excl. options
-
$898M
-
Value change
-
-$44.5M
-
Put/Call ratio
-
1.09
-
Number of buys
-
85
-
Number of sells
-
-67
-
Price
-
$7.45
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2020
208 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2020.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 210M outstanding shares and own 57.5% of the company stock.
Largest 10 shareholders include BlackRock Inc. (16.3M shares), BAKER BROS. ADVISORS LP (12.7M shares), VANGUARD GROUP INC (11.6M shares), STATE STREET CORP (11.1M shares), Sarissa Capital Management LP (8.18M shares), CITADEL ADVISORS LLC (6.5M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (5.84M shares), Point72 Asset Management, L.P. (3.23M shares), ORACLE INVESTMENT MANAGEMENT INC (2.98M shares), and Marshall Wace North America L.P. (2.8M shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.